Sign in
Not yet taking people in South KoreaPhase 3

Zenagamtide weekly injections for weight loss in Asian adults with overweight or obesity

Tests zenagamtide against placebo in Asian adults with overweight or obesity.

Key facts

Who runs it
Novo Nordisk A/S
Where
Daegu, Seoul, Seoungnam-si, Suwon, and Yangsan, South KoreaSee the 7 sitesAlso in 4 other countries, 37 sites
Trial code
Registry title
AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight
Status
Not yet recruiting
Phase
Phase 3
People taking part
400 people, planned
Starts
7 Jan 2027
Expected to end
11 Jan 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Zenagamtide
  • Placebo ( matched to Zenagamtide)
Record updated
24 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in Asia with excess body weight (overweight or obesity). It tests a weekly injection called zenagamtide against placebo.

Age
18 years or older
Sex
Men and women can join
Disease stage
Overweight or obesity
Earlier treatment
People who had GLP-1 receptor agonists, dual GLP-1/GIP receptor agonists (or any other GLP-1 based treatment) or amylin analogues before screening cannot join

Main reasons for not taking part

  • HbA1c of 6.5% (48 mmol/mol) or higher at screening
  • History of type 1 or type 2 diabetes
  • Earlier treatment with GLP-1 receptor agonists, dual GLP-1/GIP receptor agonists or amylin analogues

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Male or female (sex assigned at birth, inclusive of all gender identities)
  • Age 18 years or above at the time of signing the informed consent

Who cannot take part

  • Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening
  • History of type 1 or type 2 diabetes mellitus
  • Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening

Where in South Korea

Also in 4 other countries, 37 sites

  • Kyungpook National University Hospital_Family MedicineDaegu, South KoreaContact: Novo NordiskNot yet recruiting
  • Konkuk University Medical Center_EndocrinologySeoul, South KoreaContact: Novo NordiskNot yet recruiting
  • Seoul National University Hospital_Family MedicineSeoul, South KoreaContact: Novo NordiskNot yet recruiting
  • Severance Hospital, Yonsei University Health System_Family MedicineSeoul, South KoreaContact: Novo NordiskNot yet recruiting
  • Seoul National University Bundang Hospital_EndocrinologySeoungnam-si, South KoreaContact: Novo NordiskNot yet recruiting
  • Ajou University Hospital_Family MedicineSuwon, South KoreaContact: Novo NordiskNot yet recruiting
  • Pusan National University Yangsan Hospital_Family MedicineYangsan, South KoreaContact: Novo NordiskNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide (the treatment being tested) or placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

The 2 groups in the trial

  • ZenagamtideTreatment being tested

    Participants will be randomized to receive 1 out of 3 different dose levels subcutaneously once weekly.

  • PlaceboPlacebo, for comparison

    Participants will receive placebo matched to Zenagamtide subcutaneously once weekly.

    Treatment: Placebo ( matched to Zenagamtide)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13)
Plain-language title
Zenagamtide weekly injections for weight loss in Asian adults with overweight or obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
24 August 2026